These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 23648843)

  • 1. Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope?
    Partensky C
    Pancreas; 2013 Jul; 42(5):729-39. PubMed ID: 23648843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
    Steele CW; Oien KA; McKay CJ; Jamieson NB
    Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?
    Mardin WA; Mees ST
    Ann Surg Oncol; 2009 Nov; 16(11):3183-9. PubMed ID: 19636633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
    Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
    Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.
    Singh P; Srinivasan R; Wig JD
    Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma.
    Nakamura S; Sadakari Y; Ohtsuka T; Okayama T; Nakashima Y; Gotoh Y; Saeki K; Mori Y; Nakata K; Miyasaka Y; Onishi H; Oda Y; Goggins M; Nakamura M
    Ann Surg Oncol; 2019 Jul; 26(7):2104-2111. PubMed ID: 30820789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology.
    Mazur PK; Siveke JT
    Gut; 2012 Oct; 61(10):1488-500. PubMed ID: 21873467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma.
    Giovinazzo F; Turri G; Zanini S; Butturini G; Scarpa A; Bassi C
    Surg Oncol; 2012 Dec; 21(4):e171-82. PubMed ID: 22981281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool?
    Tarasiuk A; Mackiewicz T; Małecka-Panas E; Fichna J
    Cancer Biol Ther; 2021 Jun; 22(5-6):347-356. PubMed ID: 34224317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.
    Yabushita S; Fukamachi K; Tanaka H; Sumida K; Deguchi Y; Sukata T; Kawamura S; Uwagawa S; Suzui M; Tsuda H
    Pancreas; 2012 Oct; 41(7):1013-8. PubMed ID: 22513294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas.
    Hidalgo M; Von Hoff DD
    Clin Cancer Res; 2012 Aug; 18(16):4249-56. PubMed ID: 22896691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma.
    Mangge H; Niedrist T; Renner W; Lyer S; Alexiou C; Haybaeck J
    Curr Med Chem; 2017; 24(28):3012-3024. PubMed ID: 28494747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101.
    Qazi AM; Gruzdyn O; Semaan A; Seward S; Chamala S; Dhulipala V; Sethi S; Ali-Fehmi R; Philip PA; Bouwman DL; Weaver DW; Gruber SA; Batchu RB
    Surgery; 2012 Oct; 152(4):704-11; discussion 711-3. PubMed ID: 22943841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma.
    Szafranska AE; Davison TS; John J; Cannon T; Sipos B; Maghnouj A; Labourier E; Hahn SA
    Oncogene; 2007 Jun; 26(30):4442-52. PubMed ID: 17237814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated genomic, transcriptomic, and RNA-interference analysis of genes in somatic copy number gains in pancreatic ductal adenocarcinoma.
    Samuel N; Sayad A; Wilson G; Lemire M; Brown KR; Muthuswamy L; Hudson TJ; Moffat J
    Pancreas; 2013 Aug; 42(6):1016-26. PubMed ID: 23851435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic cancer: current understanding of molecular and genetic aetiologies.
    Gall TM; Wasan H; Jiao LR
    Postgrad Med J; 2015 Oct; 91(1080):594-600. PubMed ID: 26124188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications.
    Magee CJ; Greenhalf W; Howes N; Ghaneh P; Neoptolemos JP
    Surg Oncol; 2001; 10(1-2):1-23. PubMed ID: 11719025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational biomarkers for pancreatic adenocarcinoma: where do we stand?
    Datta J; Vollmer CM
    South Med J; 2014 Apr; 107(4):256-63. PubMed ID: 24937521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.